| Literature DB >> 33552967 |
Xin Zhou1,2, Peiyao Liu1,2, Xiaoshen Wang3.
Abstract
Cerebral radiation necrosis (CRN) is one of the most prominent sequelae following radiation therapy for nasopharyngeal carcinoma (NPC), which might have devastating effects on patients' quality of life (QOL). Advances in histopathology and neuro-radiology have shed light on the management of CRN more comprehensively, yet effective therapeutic interventions are still lacking. CRN was once regarded as progressive and irreversible, however, in the past 20 years, with the application of intensity-modulated radiation therapy (IMRT), both the incidence and severity of CRN have declined. In addition, newly developed medical agents including bevacizumab-a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), nerve growth factor (NGF), monosialotetrahexosylganglioside (GM1), etc., have shown great potency in successfully reversing radiation-induced CRN. As temporal lobes are most frequently compromised in NPC patients, this review will summarize the state-of-the-art progress regarding the incidence, pathophysiology, prevention, treatment, and prognosis of temporal lobe necrosis (TLN) after IMRT in NPC.Entities:
Keywords: bevacizumab; cerebral radiation necrosis; monosialotetrahexosylganglioside; nerve growth factor; pathophysiology
Year: 2021 PMID: 33552967 PMCID: PMC7859432 DOI: 10.3389/fonc.2020.593487
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 6.244